|
CYTH2 |
cytohesin 2 |
|
- Inositol 1,3,4,5-Tetrakisphosphate
- Formic acid
- 1D-myo-inositol 1,4,5-trisphosphate
- S,S-(2-Hydroxyethyl)Thiocysteine
- Brefeldin A
|
|
|
CYTH3 |
cytohesin 3 |
|
- Inositol 1,3,4,5-Tetrakisphosphate
- Inositol-(1,3,4,5,6)-Pentakisphosphate
|
|
|
DDX5 |
DEAD-box helicase 5 |
- SUMOylation of transcription cofactors
- mRNA Splicing - Major Pathway
- Estrogen-dependent gene expression
- Replication of the SARS-CoV-1 genome
- Replication of the SARS-CoV-2 genome
|
|
|
|
DNAJB6 |
DnaJ heat shock protein family (Hsp40) member B6 |
- Regulation of HSF1-mediated heat shock response
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
FANCC |
FA complementation group C |
- Fanconi Anemia Pathway
- TP53 Regulates Transcription of DNA Repair Genes
|
|
|
|
FASLG |
Fas ligand |
- Caspase activation via Death Receptors in the presence of ligand
- Regulation by c-FLIP
- RIPK1-mediated regulated necrosis
- CASP8 activity is inhibited
- Interleukin-4 and Interleukin-13 signaling
- Dimerization of procaspase-8
- FasL/ CD95L signaling
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- FOXO-mediated transcription of cell death genes
- TNFs bind their physiological receptors
|
|
- Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
|
|
FBP2 |
fructose-bisphosphatase 2 |
|
|
|
|
FTL |
ferritin light chain |
- Scavenging by Class A Receptors
- Golgi Associated Vesicle Biogenesis
- Neutrophil degranulation
- Iron uptake and transport
|
- Iron Dextran
- Protoporphyrin
- Ferric pyrophosphate
- Sodium ferric gluconate complex
- Ferric pyrophosphate citrate
|
- Neurodegeneration with brain iron accumulation (NBIA); Hallervorden-Spatz syndrome; Neuroferritinopathy; Aceruloplasminemia
|
|
GABRB1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
- Signaling by ERBB4
- GABA receptor activation
- GABA receptor activation
|
- Lorazepam
- Ethchlorvynol
- Enflurane
- Temazepam
- Butabarbital
- Butalbital
- Phenytoin
- Etomidate
- Talbutal
- Pentobarbital
- Clobazam
- Meprobamate
- Eszopiclone
- Alprazolam
- Lindane
- Metharbital
- Chlordiazepoxide
- Amoxapine
- Adinazolam
- Lamotrigine
- Medroxyprogesterone acetate
- Clorazepic acid
- Acamprosate
- Midazolam
- Flurazepam
- Isoflurane
- Primidone
- Halazepam
- Propofol
- Diazepam
- Oxazepam
- Triazolam
- Ethanol
- Methoxyflurane
- Memantine
- Clonazepam
- Methyprylon
- Halothane
- Desflurane
- Flumazenil
- Estazolam
- Sevoflurane
- Glutethimide
- gamma-Hydroxybutyric acid
- Camazepam
- Delorazepam
- Flunitrazepam
- Ethyl loflazepate
- Cloxazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Ketazolam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
- Prasterone
- Taurine
- Brotizolam
- Stiripentol
- Etizolam
- Thiocolchicoside
- Brexanolone
- Apalutamide
- Remimazolam
- Benzodiazepine
- Pinazepam
- Medazepam
- Loprazolam
- Doxefazepam
- Lormetazepam
- Nordazepam
- Oxazepam acetate
- Cinazepam
- Bentazepam
- Mexazolam
|
|
|
GALNT12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
- Defective GALNT12 causes colorectal cancer 1 (CRCS1)
- O-linked glycosylation of mucins
|
|
|
|
GLIS2 |
GLIS family zinc finger 2 |
|
|
- Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
|
|
GNAQ |
G protein subunit alpha q |
- Acetylcholine regulates insulin secretion
- Acetylcholine regulates insulin secretion
- G alpha (q) signalling events
- G alpha (q) signalling events
- ADP signalling through P2Y purinoceptor 1
- ADP signalling through P2Y purinoceptor 1
- Thromboxane signalling through TP receptor
- Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
- Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion
- Thrombin signalling through proteinase activated receptors (PARs)
|
|
|
|
GRIN2B |
glutamate ionotropic receptor NMDA type subunit 2B |
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- Ras activation upon Ca2+ influx through NMDA receptor
- RAF/MAP kinase cascade
- Neurexins and neuroligins
- Synaptic adhesion-like molecules
- MECP2 regulates neuronal receptors and channels
- Activated NTRK2 signals through FYN
- Assembly and cell surface presentation of NMDA receptors
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
|
- Glutamic acid
- Tramadol
- Enflurane
- Atomoxetine
- Pentobarbital
- Methadone
- Secobarbital
- Meperidine
- Haloperidol
- Acamprosate
- Donepezil
- Guaifenesin
- Felbamate
- Memantine
- Phenobarbital
- Aripiprazole
- Tenocyclidine
- Prasterone
- Taurine
- Milnacipran
- EVT-101
- Lumateperone
- Acetylcysteine
- Ketobemidone
- Gavestinel
- Ifenprodil
- Magnesium acetate tetrahydrate
- Magnesium carbonate
- Esketamine
- Esketamine
- Fluciclovine (18F)
|
|
|
HRAS |
HRas proto-oncogene, GTPase |
- SOS-mediated signalling
- Activation of RAS in B cells
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Signalling to RAS
- p38MAPK events
- p38MAPK events
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- FCERI mediated MAPK activation
- NCAM signaling for neurite out-growth
- EPHB-mediated forward signaling
- Ras activation upon Ca2+ influx through NMDA receptor
- VEGFR2 mediated cell proliferation
- CD209 (DC-SIGN) signaling
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Regulation of RAS by GAPs
- RAF activation
- RAF/MAP kinase cascade
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- RAS signaling downstream of NF1 loss-of-function variants
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Insulin receptor signalling cascade
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
- MET activates RAS signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Estrogen-stimulated signaling through PRKCZ
- RAS processing
- RAS GTPase cycle mutants
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
|
- Hexane-1,6-Diol
- Trifluoroethanol
- Guanosine-5'-Triphosphate
- Guanosine-5'-Diphosphate
- N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
- Bladder cancer
- Penile cancer
- Squamous cell carcinoma
- Thyroid cancer
- Cervical cancer
- Hepatocellular carcinoma
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
IL13RA2 |
interleukin 13 receptor subunit alpha 2 |
- Interleukin-4 and Interleukin-13 signaling
|
|
|
|
IL24 |
interleukin 24 |
- Interleukin-20 family signaling
|
|
|
|
IL3 |
interleukin 3 |
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF/MAP kinase cascade
- RUNX1 regulates transcription of genes involved in interleukin signaling
- Interleukin receptor SHC signaling
|
- Amlexanox
- Zinc
- Polaprezinc
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
IRS2 |
insulin receptor substrate 2 |
- PI3K Cascade
- IRS-mediated signalling
- SOS-mediated signalling
- SOS-mediated signalling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- PI3K/AKT activation
- PI3K/AKT activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- IRS-related events triggered by IGF1R
- Signaling by Leptin
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- RET signaling
- Signaling by Erythropoietin
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Growth hormone receptor signaling
|
|
|
|
IRS4 |
insulin receptor substrate 4 |
- IRS-related events triggered by IGF1R
|
|
|